Company intelligence / Profile preview

Xinda Biopharmaceutical Support

Ownership: Private
Development stage: Commercial

Overview

As of early 2016, the company had secured significant overseas investment ($232 million), established strategic cooperation with Eli Lilly, and was developing a pipeline of at least ten proprietary monoclonal antibody drugs targeting cancer, diabetes, and autoimmune diseases. No recent clinical results or approvals are reported in the available sources.

Therapeutic areas: OncologyEndocrinologyImmunology
Modalities: Monoclonal antibodies (mAbs)Small molecules
Industry: Biotech

Drug pipeline

5 assets

sintilimab

Commercial

Indications: Cancer

4 more assets in the full pipeline.

Request access →

Partnerships

Eli Lilly (strategic cooperation established in 2015)

Beyond the preview

Go deeper on Xinda Biopharmaceutical Support.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinda Biopharmaceutical Support.

Explore the full profile